

Article

# Electrospun Fibrous Architectures for Localized Delivery of Photosensitizers in Cancer Therapy

Cátia V. Gomes <sup>1</sup>, Sofia M. Costa <sup>1,\*</sup>, João S. Oliveira <sup>1</sup>, Ricardo C. Calhella <sup>2</sup>, Leandro M. O. Lourenço <sup>3</sup>, Raul Fangueiro <sup>1</sup> and Diana P. Ferreira <sup>1,\*</sup>

<sup>1</sup> Centre for Textile Science and Technology (2C2T), University of Minho, 4800-058 Guimarães, Portugal

<sup>2</sup> Mountain Research Center (CIMO), Associated Laboratory for Sustainability and Technology in Inland Regions (LA SusTEC), Instituto Politécnico de Bragança, Campus de Santa Apolónia, 5300-253 Bragança, Portugal

<sup>3</sup> Laboratório Associado para a Química Verde (LAQV-REQUIMTE), Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal

\* Correspondence: sofiamcosta@2c2t.uminho.pt (S.M.C.); diana.ferreira@det.uminho.pt (D.P.F.)

## Abstract

Photodynamic therapy (PDT) is a promising localized strategy for the treatment of cervical cancer, ranking as the fourth most common cancer among women worldwide. The integration of photosensitizers (PSs) in localized drug delivery systems (DDSs), particularly in electrospun nanofibers, holds tremendous potential to overcome the drawbacks of their systemic administration. Exploring multilayer fibrous architectures provides a versatile therapeutic platform to design the next generation of localized DDS. In this work, localized implants for cancer treatment using PDT were developed using polyhydroxyalkanoate (PHA), chitosan (CS) and polyethylene oxide (PEO) as biopolymers and a porphyrin (Por) as PS, following two approaches: blended PHA/Por electrospun microfibers and multilayered membranes (PHA–Por/CS/PEO) produced by sequential electrospinning. The synthesized Por displayed higher cytotoxicity in light compared to dark against tumor cells. All the developed membranes were characterized regarding their morphology, wettability, absorption and fluorescence properties. PHA–Por membranes exhibited overall uniform fibrous morphologies with successful Por incorporation. Nonetheless, they presented a highly hydrophobic surface, compromising the Por release and cell–material interactions. In contrast, multilayer PHA–Por/CS/PEO membranes demonstrated enhanced hydrophilicity and enabled sustained Por release. Upon light irradiation, these membranes induced a significantly greater inhibition of HeLa cell proliferation (29.61%) compared to dark conditions (6.21%), confirming their photodynamic activity.

**Keywords:** cancer; photodynamic therapy; localized drug delivery systems; biopolymers; electrospinning; multilayer fibrous structures



Academic Editors: Ildikó Katalin Bácskay and Petra Arany

Received: 21 January 2026

Revised: 25 February 2026

Accepted: 27 February 2026

Published: 3 March 2026

**Copyright:** © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the [Creative Commons Attribution \(CC BY\) license](https://creativecommons.org/licenses/by/4.0/).

## 1. Introduction

Cancer represents one of the most significant global public health challenges, being the leading cause of death worldwide [1]. Among them, cervical cancer stands out as the fourth most common cancer among women globally, accounting for 660,000 new cases and around 350,000 deaths in 2022 [2]. The persistent infection with high-risk genotypes of human papillomavirus (HPV) is the primary cause of this type of cancer. Despite the significant advancements in prevention through HPV vaccination and screening, as well as in therapeutic strategies over the past few decades, achieving efficient treatments

with minimal side effects is still a major challenge. The standard therapeutic approaches for cervical cancer usually include surgical resection, radiotherapy, chemotherapy, or a combination of them, with the determination of the proper treatment regimen dependent on the stage and extent of cervical cancer progression [3,4]. Nevertheless, they still face several limitations, such as recurrence, fertility loss, early miscarriage, premature delivery, cervical canal stenosis, potential urinary dysfunction, diarrhoea, and pelvic pain, among others [4–6]. These challenges emphasize the need for more precise, targeted and personalized therapeutic interventions.

Photodynamic therapy (PDT) has arisen as a promising therapeutic modality due to its minimal invasiveness, localized character, repeatability at the same region multiple times without inducing tumor resistance or tissue hypersensitivity, and possibility to be combined with other therapeutic strategies [7]. This therapy involves the administration of a photoactive molecule (photosensitizer, PS), followed by its uptake by the target cells, and the subsequent irradiation of the PS with light of an adequate wavelength. The PS's activation by light will generate reactive oxygen species (ROS) that promote cell structural and functional failure, thereby destroying target cells/tissues [8,9].

Several PSs have been approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of various types of cancers and precancerous lesions using PDT, including, but not limited to, skin, breast and esophageal cancer, advanced squamous cell carcinoma of the head and neck [10]. Among them, porphyrins and some derivatives are the most widely used PSs in PDT due to their favorable properties, namely high purity, long triplet state lifetime, high  $^1\text{O}_2$  quantum yield ( $\Phi_\Delta$ ), minimal dark toxicity, and in some cases rapid clearance from the patient's body [11,12].

Despite the promising results and growing clinical applications, PDT still faces some obstacles to its widespread use, particularly when PSs are administered systemically. Those include low bioavailability at the tumor site, which may result in high dose requirements; poor tumor-targeting efficacy, which limits their accumulation and penetration in tumor tissues; limited solubility; aggregation under physiological conditions; and limited light penetration depth within tissues, making it difficult to effectively treat deep-seated tumors, among others. Therefore, the incorporation of PSs into localized drug delivery systems (DDS) holds tremendous potential to overcome inherent limitations of PSs and light delivery issues [12,13].

Recent advances in nanotechnology have enabled the development of novel and more effective localized DDS able to prevent premature drug degradation, control drug release in the target sites, minimize exposure to healthy tissues and prolong drug residence at the treatment site [14]. Electrospinning technique emerges as a key driver in the future of localized DDS, due to its ability to develop customizable nanofiber architectures, offering precise control over their morphology, composition, and functionality together with accuracy, versatility, cost-effectiveness, simplicity and upscaling possibility [15–17].

Electrospun membranes composed of fibers from micro- to nanoscale display unique properties, giving them a high potential for localized drug delivery. Some of them include high surface area, high porosity with interconnectivity, high drug encapsulation efficiency, surface functionalization, flexibility, conformability to adapt to the tissue morphology, and control over the drug release profile. The resemblance to extracellular matrix (ECM) structure is a fundamental advantage of these nanostructures since it promotes cell–material interactions. Tailoring the matrix materials and the structure of the fibrous membranes allows the customization of these nanoplatforms to meet patients' specific characteristics, unlocking the potential for personalized medicine [10,18]. Additionally, multilayered fibrous architectures with layer-specific materials and morphologies can be produced by sequential electrospinning, joining properties of the different materials and layers [18].

This therapeutic approach combining PDT and electrospun nanofibers as DDS holds great potential for cervical cancer treatment due to the anatomical accessibility of the cervix through the vaginal canal for both implantation of the DDS as well as the tissue illumination [19,20].

Polymers of natural origin are being increasingly explored for medical applications, due to their intrinsic biocompatibility, non-toxicity and biodegradability, aligned with the growing industry requirements for the development of environmentally sustainable solutions [21–23]. Polyhydroxyalkanoates (PHAs) are natural polyesters synthesized by certain bacteria and other microorganisms as an energy source during periods of unstable growth [24]. This class of biopolymers has been widely studied for regenerative medicine and drug delivery owing to their renewable origin, biodegradability, biocompatibility and exceptional adaptability [25]. Despite the great features of PHA-based materials, some of the features, like high production costs, low thermal stability, slow degradation rate and high hydrophobicity, may limit their use in the medical field [24].

Hence, surface modification strategies offer an effective approach to overcome the intrinsic hydrophobicity of PHA-based materials and to enhance their biological performance. Improving their surface hydrophilicity is a key factor for protein adsorption and cell adhesion, thereby strengthening cell–material interactions and improving overall biocompatibility and biological response [26]. This strategy can be addressed by coating the PHA surface with hydrophilic compounds. For instance, PHA electrospun membranes can be coated with an additional layer of hydrophilic nanofibers composed of biopolymers such as chitosan (CS) and polyethylene oxide (PEO) via sequential electrospinning, thereby enhancing surface wettability, structural integrity and cell interactivity. These multilayer fibrous architectures enable each layer to meet specific functional requirements, integrating distinct morphologies and materials to maximize their potential [20,27]. This combination provides a versatile therapeutic platform to design advanced and multifunctional nanofibrous structures with superior performance for cancer treatment using PDT.


Therefore, the main objective of this work was to evaluate the potential of different architectures of therapeutic fibrous platforms based on electrospun membranes to act as localized DDS for cervical cancer treatment using PDT. A tetra-substituted thioglycerol porphyrin,  $H_2TPPF_{16}[SC_3H_7O_2]_4$ , was used as PS. In this study, two approaches were followed: (i) development of blended PHA/Por electrospun microfibers and (ii) multilayered membranes (PHA–Por/CS/PEO) by sequential electrospinning. In the latter, the middle PHA-based layer, post-functionalized with Por, provides mechanical integrity and controlled release of therapeutic molecules, while the outer layers, composed of CS and PEO, improve the surface hydrophilicity. The developed electrospun membranes were fully characterized by Field Emission Scanning Electron Microscopy (FESEM), Attenuated Total Reflectance-Fourier Transform Infrared Spectroscopy (ATR-FTIR), Thermogravimetric Analysis (TGA), Water Contact Angle (WCA), UV–visible and fluorescence spectroscopy, Ground State Diffuse Reflectance (GSDR), Confocal Laser Scanning Microscopy (CLSM) and Energy Dispersive Spectroscopy (EDS). Finally, the Por release from membranes was assessed, and the *in vitro* dark- and light-cytotoxicity was evaluated.

## 2. Results and Discussion

### 2.1. Development of PHA Electrospun Membranes

PHA membranes were developed by electrospinning and characterized by FESEM, ATR-FTIR and TGA analyses, to assess their morphology and diameters, chemical composition and thermal stability, respectively (Figure 1). PHA membranes were developed by electrospinning with a very uniform deposition, and they were easily detached from the aluminium foil, as can be seen in Figure 1a. Their morphology, assessed by FESEM

images, revealed the successful production of uniform microfibers with average diameters of 1.3  $\mu\text{m}$ , confirmed by the diameter distribution histogram (Figure 1b).



**Figure 1.** Morphological, chemical and thermal characterization of PHA electrospun membranes. (a) Picture and (b) FESEM images of PHA membranes and the respective diameter distribution histogram. The images were obtained using different magnifications: 100, 20, 10 and 2  $\mu\text{m}$ . (c) TGA and first-order DTG and (d) ATR-FTIR spectrum of PHA membranes.


To assess the thermal stability of the produced electrospun membranes, TGA analysis was carried out by subjecting the samples to controlled heating up to 600 °C. The thermal decomposition behavior of PHA microfibers is shown in Figure 1c. The TGA and derivative thermogravimetry (DTG) curves of PHA showed two main degradation stages: the first stage, which is associated with PHA degradation, occurs between 200 and 300 °C, with a weight loss of 59% and a maximum degradation peak at 270 °C; the second stage occurs at 300–370 °C, presenting a weight loss of 37%, and it is associated with the degradation of polylactic acid (PLA). Ideally, pure PHA would have only one degradation step [28–30]. However, the blending of commercially synthesized materials is a common practice that can enhance the mechanical and thermal properties of the commercialized polymer [29–31].

The chemical composition of electrospun membranes was evaluated by ATR-FTIR (Figure 1d), with the main bands described as follows. The bands at 2993 and 2937  $\text{cm}^{-1}$  are attributed to C-H stretching vibration [32]. The most intense band of the PHA spectrum is located at 1722  $\text{cm}^{-1}$ , which relates to the stretching vibration of the ester carbonyl group (C=O) and indicates the crystalline phase [33]. The bands detected at 1453 and 1380  $\text{cm}^{-1}$  are attributed to the bending of CH<sub>2</sub> and CH<sub>3</sub> groups, respectively [34]. The ones at 1276 and 1180  $\text{cm}^{-1}$  correspond to the asymmetric and symmetric stretching vibrations of C-O-C and C-O, respectively [35]. Finally, the band at 1085  $\text{cm}^{-1}$  is attributed to C-O stretching, the band at 1054  $\text{cm}^{-1}$  to C-O symmetric stretching or to C-CH<sub>3</sub> bending, and the band at 979  $\text{cm}^{-1}$  to C-H bending or C-C or C-O-C stretching [33,34,36]. Some of these bands are also characteristics of PLA, including those in 1722, 1453, 1180 and 1085  $\text{cm}^{-1}$  [37,38]. These findings demonstrate that the developed electrospun membranes are composed of PHA and PLA polymers.

## 2.2. Development of PHA/Por Electrospun Membranes

### 2.2.1. Cytotoxic Studies of Porphyrin in HeLa Cells

Detailed characterization of the synthesized Por was recently reported by coauthors [39,40].  $\text{H}_2\text{TPPF}_{16}[\text{SC}_3\text{H}_7\text{O}_2]_4$  displayed excellent properties to be considered a good PS, such as high  $^1\text{O}_2$  generation, good photostability, high fluorescence quantum yields, and photodynamic activity against human bladder cancer cells [39]. In this work, the absorption and fluorescence properties of the synthesized Por were also studied (Figure 2a). A typical porphyrin electronic absorption spectrum shows two distinct dominant regions. The first one refers to the transition from the ground state to the second excited state ( $S_0 \rightarrow S_2$ ), corresponding to the Soret or B band, with a maximum absorption between 380 and 500 nm. The second region consists of a transition from the ground state to the first excited state ( $S_0 \rightarrow S_1$ ) between 500 and 700 nm, corresponding to the Q bands [11,12]. The normalized absorption spectrum of the Por in dimethylformamide (DMF) is characterized by a strong Soret band with maximum absorption at 414 nm, and four moderate Q bands at 506, 539, 582 and 653 nm. The normalized fluorescence spectrum of Por in solution shows a strong emission between 600 and 800 nm. The capacity to emit fluorescence can be useful to act as a theranostic agent, allowing both diagnosis by image and treatment [41].




**Figure 2.** (a) Normalized absorption and fluorescence emission ( $\lambda_{\text{exc.}} = 365$  nm) spectra of the Por in DMF. (b) Cytotoxicity ( $\text{GI}_{50}$  values,  $\mu\text{M}$ ; mean  $\pm$  SD) of Por in the dark (control) and under light irradiation.

To evaluate the photodynamic effect of these molecules in a cervical carcinoma cell line, the cytotoxicity of the Por in dark and light conditions was determined against HeLa cells. The results are expressed in concentration values needed to inhibit 50% of cell growth ( $\text{GI}_{50}$ ; Figure 2b). In dark conditions, free Por inhibited 50% of HeLa growth at a concentration of  $5.29 \mu\text{M}$ . However, upon light irradiation, the  $\text{GI}_{50}$  value considerably decreased to  $0.51 \mu\text{M}$ , indicating that a lower amount of the compound is required to inhibit cancer cell growth when exposed to radiation and confirming the need for light for Por's activation. These findings demonstrated the photodynamic effect of Por in this cell line, since  $\text{H}_2\text{TPPF}_{16}[\text{SC}_3\text{H}_7\text{O}_2]_4$  exhibited about 10 times more cytotoxicity under light than in dark conditions.

### 2.2.2. Characterization of PHA/Por Electrospun Membranes

Based on the obtained phototoxicity value of Por in its free form (Figure 2b), PHA electrospun membranes were functionalized with different Por concentrations, namely  $5.1 \times 10^{-7}$ ,  $1.02 \times 10^{-5}$ ,  $5.1 \times 10^{-5}$  and  $5.1 \times 10^{-4}$  M, to correspond to  $1\times$ ,  $20\times$ ,  $100\times$  and  $1000\times$  of the obtained  $\text{GI}_{50}$  value under light irradiation, respectively. PHA/Por membranes were characterized regarding their morphology, diameters, absorption, and fluorescence properties (Figure 3) and, when applicable, compared to PHA membranes used as the control group.



**Figure 3.** Morphology, diameters, absorption and fluorescence characterization of PHA/Por electrospun membranes. (a) FESEM images of PHA/Por membranes at different Por concentrations ( $5.1 \times 10^{-7}$ ,  $1.02 \times 10^{-5}$ ,  $5.1 \times 10^{-5}$  and  $5.1 \times 10^{-4}$  M), and their respective diameter distribution histograms. The images were obtained using different magnifications: 200, 100 and 20  $\mu\text{m}$ . (b) GSDR and (c) fluorescence emission ( $\lambda_{\text{exc.}} = 365$  nm) spectra and (d) CLSM images of PHA (control) and PHA/Por membranes.

The fibers' morphology appears to be preserved after the incorporation of Por at distinct concentrations, according to FESEM images (Figure 3a). The average diameters of the microfibers changed from 1.3  $\mu\text{m}$  to 0.9, 1.6, 1.9 and 1.6  $\mu\text{m}$  with the addition of  $5.1 \times 10^{-7}$ ,  $1.02 \times 10^{-5}$ ,  $5.1 \times 10^{-5}$  and  $5.1 \times 10^{-4}$  M of Por, respectively. As demonstrated by the histograms, the fibers' diameter distribution was very homogeneous, showing the development of uniform structures with regular diameters. Incorporating the highest Por concentration ( $5.1 \times 10^{-4}$  M) not only resulted in the appearance of some beads but also in a more heterogeneous diameter distribution, with a minimum value detected at 0.5  $\mu\text{m}$  and a maximum at 4.4  $\mu\text{m}$ . This finding may suggest that this Por concentration is excessive, which could cause the dye molecules to aggregate and create structural defects in the electrospun membranes, compromising their performance.


To evaluate the presence of Por within the microfibers, the Kubelka–Munk remission function was calculated following Equation (1), and the obtained spectra are presented

in Figure 3b. As expected, PHA membranes did not show any absorption band. On the other hand, PHA/Por membranes showed the appearance of the characteristic absorption bands of this dye, confirming the successful incorporation of the compound within the developed membranes. The intensity of these bands increased gradually according to the Por concentration. The Soret band was detected at 417 nm, as well as the four Q bands.

The fluorescence spectrum of PHA membranes showed no emission band (Figure 3c), whereas the spectra of PHA/Por membranes showed a strong emission band between 600 and 800 nm, similar to the behavior of Por in solution (Figure 2a). Increasing Por concentration promoted an increase in the fluorescence bands' intensity. These bands widened at the highest concentration of Por, which may indicate dye agglomeration [42]. The CLSM technique was used to study the presence and distribution of Por in the membranes (Figure 3d). PHA/Por membranes displayed fluorescence in the red region, with this signal being more pronounced with  $5.1 \times 10^{-5}$  and  $5.1 \times 10^{-4}$  M of Por. In the PHA +  $5.1 \times 10^{-4}$  M Por membrane, the areas of higher fluorescence intensity, indicative of a higher Por amount in the membranes, proved that the compound was evenly distributed throughout the fibers, with a few agglomerates being found. This confirms the preservation of the Por's fluorescence properties after being encapsulated within fibrous structures, a crucial aspect of theranostic platforms that allow simultaneous diagnosis and therapy [43].

### 2.2.3. Por Release Profile and Surface Wettability of PHA-Based Electrospun Membranes

To investigate the release behavior of Por from polymeric microfibers, the membranes were immersed in a release medium consisting of PBS solution (pH 7.4, 37 °C) for 24 h. PHA +  $5.1 \times 10^{-4}$  M Por membrane was used as an example, with the release of Por monitored by UV–Vis spectroscopy (Figure 4a). Over 24 h, no absorption bands of Por were detected, suggesting that this dye is not being released from microfibers during that period under physiological conditions. The hydrophobic character of PHA-based electrospun membranes may be one of the factors contributing to this finding. In fact, PHA membranes displayed a WCA of 139° (Figure 4b), indicating high surface hydrophobicity. PHA/Por presented a WCA of 127°, 130°, 134° and 121°, according to the Por concentration. Although a slight decrease in WCA occurred with increasing Por incorporation, the membranes remained highly hydrophobic. The intrinsic hydrophobic nature and slow degradation rate of PHA may discourage its use in several advanced biomedical applications [44]. In fact, surface wettability plays an important role in cell–material interactions. Generally, hydrophilic surfaces favor cell adhesion and biological response, enhancing biocompatibility and targeted drug delivery to the tumor site. In this context, surface modification strategies aimed at increasing the hydrophilicity of PHA-based membranes hold promising potential to improve cell adhesion and overall biocompatibility [26,45].



**Figure 4.** (a) Absorption spectra of the release medium obtained using PHA +  $5.1 \times 10^{-4}$  M Por electrospun membranes over 24 h. (b) WCA of PHA and PHA/Por membranes with different Por concentrations ( $5.1 \times 10^{-7}$ ,  $1.02 \times 10^{-5}$ ,  $5.1 \times 10^{-5}$  and  $5.1 \times 10^{-4}$  M).

### 2.3. Multilayered Electrospun Membranes: PHA–Por/CS/PEO


A new concept was then pursued to create a hydrophilic surface to improve material–cell compatibility while potentially facilitating an increased Por release rate. This approach was based on the production of a multilayer membrane able to release the PS in a controlled but faster manner, while endowed with surface hydrophilicity. The multilayered membranes consisted of (i) outer layers composed of electrospun CS/PEO nanofibers, and (ii) a middle layer composed of electrospun PHA microfibers, with a post-electrospinning coating with Por solution. In the surface layers, CS and PEO, as hydrophilic polymers, will enhance biocompatibility between the implant and cells while ensuring a more precise and targeted drug delivery to the tumor site. Additionally, the well-known antimicrobial properties of CS make this biopolymer very promising for drug delivery applications since it can prevent biofilm formation [27]. The middle layer consists of an electrospun PHA membrane, a hydrophobic structure that provides structural integrity and enhances the membrane's mechanical properties.

To produce these multilayer fibrous structures, PHA membranes were first prepared by electrospinning (Figure 5a), followed by post-electrospinning impregnation with Por solution ( $5.1 \times 10^{-5}$  M), resulting in PHA–Por membranes. To endow the membrane's surface with hydrophilicity, a CS/PEO nanofibrous coating was applied to both sides of the PHA–Por membranes by electrospinning, producing PHA–Por/CS/PEO electrospun membranes (Figure 5b). The difference in the colour and roughness of the membranes was clearly visible, due to the presence of Por and the CS/PEO nanofibrous coating. WCA measurements were performed to evaluate the effect of the CS/PEO nanofibrous coating on the membrane's surface wettability. This coating significantly improved the hydrophilic character of the membranes, as shown by a reduction in the average WCA from  $139^\circ$  for PHA and  $128^\circ$  for PHA–Por, a highly hydrophobic surface, to  $78^\circ$  for PHA–Por/CS/PEO, corresponding to a hydrophilic structure. Consistent with these findings, several studies have reported the intrinsically hydrophilic nature of CS/PEO electrospun nanofibers, with water contact angle values as low as  $30^\circ$  [46,47], confirming the contribution of these polymers to surface wettability. The hydrophilic character is attributed to the presence of hydroxyl functional groups in the CS structure, which promote hydrogen bonding with water molecules and facilitate water diffusion, which is an advantageous feature for DDS [48]. In parallel, PEO contributes to the overall hydrophilicity of the membranes by interacting with hydrophobic polymers and forming hydrogen bonds, enhancing surface wettability [49].

FESEM images (Figure 5c) demonstrated successful coating with CS/PEO nanofibers on the surface of PHA fibers. Additionally, cross-sectional images clearly revealed the presence of two distinct layers (Figure 5d): the middle layer corresponds to PHA microfibers, while the outside ones are from CS/PEO nanofibers. The incorporation of the CS/PEO nanofibers may also contribute to increasing the overall surface area of the membranes [27]. The randomly oriented nanoscale fibers produced by electrospinning form a network that resembles the architecture of ECM, thereby promoting enhanced biocompatibility and facilitating cell adhesion [50]. It may also contribute to an increase in specific surface area, enabling more effective membrane–cell interactions [51].


The developed multilayered membranes were also evaluated by ATR-FTIR, GSDR and fluorescence properties (Figure 6). ATR-FTIR spectrum of CS/PEO nanofibers (Figure 6a) shows the typical bands of CS and PEO polymers. A broad band at  $3368\text{ cm}^{-1}$  is observed and can be attributed to O-H and N-H stretching vibrations, which are characteristic of CS. Moreover, a band at  $2882\text{ cm}^{-1}$  is assigned to symmetric and asymmetric C-H vibrations, both in CS and PEO. In addition, the bands at  $1657$  and  $1558\text{ cm}^{-1}$  correspond to amide I (C=O stretching) and amide II (N-H bending), respectively, while the bands

located in the region of  $1242\text{--}841\text{ cm}^{-1}$  are associated with the saccharide region present in CS. Additionally, the bands at  $1146$ ,  $1099$  and  $1061\text{ cm}^{-1}$  as triplet peaks are from C–O–C stretching vibrations of PEO [27]. Thus, the interaction between CS and PEO is confirmed by the presence of the characteristic bands of both polymers. Regarding the PHA–Por/CS/PEO membrane spectrum, the presence of CS/PEO nanofibrous coating onto PHA–Por microfibers is confirmed by the appearance of the typical bands of CS/PEO along with the characteristic bands of PHA.



**Figure 5.** Morphology and hydrophilic character of PHA–Por/CS/PEO multilayered electrospun membranes. (a) Image of PHA membrane and (b) image and average water contact angle (WCA) of PHA–Por/CS/PEO membrane; FESEM images of the (c) surface and (d) cross-section of PHA–Por/CS/PEO membrane.

The GSDR spectrum (Figure 6b) of the PHA–Por/CS/PEO membrane shows the typical absorption bands of Por, confirming the successful integration of the compound on the developed multilayer membranes. The Soret band was detected at  $415\text{ nm}$ , while the four Q bands were observed at  $507$ ,  $540$ ,  $582$  and  $654\text{ nm}$ , as clearly shown in the zoomed area of Figure 6b. The fluorescence spectrum (Figure 6c) of the multilayer membrane displayed the characteristic emission bands of Por, confirming the preservation of its fluorescence properties. All these findings confirm the successful functionalization of PHA membrane with Por solution as well as the development of multilayer membranes capable of maintaining the absorption and fluorescence properties of the PS.




**Figure 6.** Chemical, absorption, and fluorescence characterization of PHA-Por/CS/PEO electrospun multilayered membranes. (a) ATR-FTIR, (b) GSDR and (c) fluorescence emission spectra of PHA-Por/CS/PEO membranes.

#### 2.4. Photodynamic Therapy-Assisted Cervical Cancer Treatment Using Localized DDS Based on Multilayer Fibrous Membranes

To assess the photodynamic effect of the developed electrospun multilayered fibrous structures, the cytotoxicity of PHA-Por ( $5.1 \times 10^{-5}$  M)/CS/PEO membrane was evaluated against cervical tumor cells in the dark and under light irradiation, comparing the results with those obtained for the PHA membrane used as a control group. Hence, the membranes were put in contact with HeLa cells for 24 h, followed by their removal and cell irradiation. Afterward, the inhibition percentage of each membrane on HeLa cells proliferation was determined for dark (used as control conditions) and light conditions (Figure 7a). The inhibition percentage of cell proliferation indicates the ability of the electrospun membranes to prevent tumor cell growth. Therefore, an increase in inhibition values is associated with a decrease in cancer cell growth [52].

PHA membrane showed a percentage of inhibition of 3.41% in the dark and 9.58% under light irradiation, demonstrating minimal toxicity. Although this slight effect may be associated with the potential presence of trace residual solvents (e.g., DMF or chloroform) used during PHA dissolution, no quantitative analysis of solvent residues was conducted. Thus, a direct correlation between residual solvent content and the observed inhibition cannot be confirmed based on the current data, and this hypothesis should be interpreted with caution. The multilayer membranes incorporated with Por exhibited a percentage of inhibition of 6.21% and 29.61% in dark conditions and when exposed to light, respectively, after 24 h of contact with the cells. In a comparable study employing porphyrin-loaded core-shell nanofibers, approximately 33% inhibition was reported at the  $GI_{50}$  concentration, while inhibition increased to nearly 90% when the porphyrin concentration was 100 times

the  $GI_{50}$  value [12]. These findings suggest that the developed multilayer structure yields lower inhibition levels with similar  $GI_{50}$  thresholds, which may be attributed to membrane architecture and/or porphyrin distribution. Accordingly, strategies such as increasing the Por loading concentration or extending the exposure time between the multilayer membrane and the cells should be studied as potential approaches to enhance the observed inhibition levels and improve the overall photodynamic efficacy of the developed system. The higher percentage of inhibition of HeLa cells upon light irradiation than in the dark (23.4% higher) demonstrates the preservation of the phototoxic effect of Por molecules after their incorporation into fibrous structures. This finding suggests that ROS are mainly generated in the presence of light, indicating the necessity of light for drug activation. This type of response is desirable in PDT for tumor treatment, as selective activation in the presence of light can target cytotoxic effects on the intended cells. Although the phototoxic effects observed under light radiation support the photoactivation of the Por within the multilayer system, no direct quantification of ROS generation was conducted. Therefore, further studies including specific ROS detection and quantification assays will be necessary to comprehend the photodynamic mechanism of the Por within the multilayer structure.



**Figure 7.** Photodynamic effect of multilayered electrospun membranes. **(a)** Inhibition percentage (% mean  $\pm$  standard deviation) of PHA (control) and PHA-Por/CS-PEO membrane on the proliferation of HeLa cells in dark and light-exposed experimental conditions. **(b)** Absorption spectra of the release medium obtained using PHA-Por ( $5.1 \times 10^{-5}$  M)/CS-PEO membrane over 316 h. **(c)** EDS analysis of PHA-Por/CS-PEO membrane after immersion in PBS solution for 24 h.

The release profile of Por from the multilayer membranes after the evaluated PDT period (24 h), together with the membrane morphology observed during this period, supports the *in vitro* photodynamic findings (Figure 7b,c). For release assessment, membranes were immersed in PBS (pH 7.4, 37 °C), and the release medium was monitored by UV-visible spectroscopy at selected time points. The spectrum at 0 h was acquired immediately after immersion, and as expected, no Por absorption bands were detected. Up to 4 h, no characteristic Por bands were observed, indicating the absence of immediate release, which may be associated with the presence of the CS/PEO outer layers acting as an interfacial barrier. At 6 h, the Soret band became clearly visible, with a marked increase in intensity up to 24 h, indicating time-dependent Por release into the medium. This behavior may be explained

primarily by the porosity and hydrophilicity of the CS/PEO nanofibrous coating, which facilitates water uptake and promotes Por diffusion through the hydrated fibrous network and inter-fiber pores [12]. Beyond increasing surface wettability, the CS/PEO layers are expected to function as a hydrated and swellable interfacial coating. Upon immersion, PEO rapidly hydrates and facilitates water penetration into the fibrous network, while the CS/PEO coating introduces an additional transport pathway that can act as a diffusion barrier for Por. This interfacial layer can mitigate burst release by temporarily retaining Por through intermolecular interactions and by increasing the effective diffusion distance, ultimately contributing to a more sustained and controlled release profile. Moreover, the presence of chitosan provides a functional, cationic interface that may promote hydrogen-bonding/electrostatic interactions with Por, contributing to a more gradual release into the medium. In addition, the partial disintegration of the CS/PEO outer layers after immersion in PBS (confirmed by SEM/EDS after 24 h) may further contribute to Por exposure and continued release. Importantly, the partial disintegration observed after 24 h refers to the CS/PEO outer nanofibrous layers and does not represent a quantified degradation onset of the middle PHA-based structural layer. A dedicated degradation-kinetics study of the middle layer was not performed in the present work; therefore, no degradation onset time is assigned to that layer. Nevertheless, Por release remained detectable up to 316 h, indicating sustained Por availability over the monitored period. It should also be noted that the release experiment presented here was intended as a qualitative proof-of-concept assessment based on the temporal evolution of the UV–visible spectral profile; therefore, quantitative release metrics (e.g., cumulative release percentage, released mass per unit area, and kinetic model fitting) were not established in the present study, and the release behavior is interpreted in descriptive/comparative terms only.

### 3. Materials and Methods

#### 3.1. Materials

Polyhydroxyalkanoate (PHA) was supplied by GoodFellow (Delson, QC, USA). The polymers, CS (high molecular weight, 310,000–375,000 Da) and PEO (molecular weight 900 kDa), and the solvents, chloroform and DMF, were purchased from Sigma-Aldrich (St. Louis, MO, USA). Glacial acetic acid 99–100% a.r. was purchased from Normax (Cambridgeshire, UK). GraphPad Prism 8.0.2 (Boston, MA, USA) and OriginPro 9.0 (Northampton, MA, USA) were utilized.


#### 3.2. Synthesis of $H_2TPPF_{16}[SC_3H_7O_2]_4$ Porphyrin

The tetra-substituted thioglycerol porphyrin  $H_2TPPF_{16}[SC_3H_7O_2]_4$  was obtained through an aromatic nucleophilic substitution on the available 5,10,15,20-tetrakis (pentafluorophenyl)-21H,23H-porphyrin ( $H_2TPPF_{20}$ ) [40] with 1-thioglycerol, under basic conditions using triethylamine, stirring for 48 h at 40 °C in DMF. The prepared compound was obtained as a dark brown solid in 89% of yield, being their structure confirmed by nuclear magnetic resonance spectroscopy techniques, as well as by mass spectrometry (Figure 8).

#### 3.3. In Vitro Photocytotoxicity of the Synthesized Porphyrin on HeLa Cell Line

The human tumor cell line HeLa (cervical carcinoma) was purchased by DSMZ (Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Braunschweig, Germany). Cells were routinely maintained as adherent cell cultures in RPMI-1640 medium containing 10% heat-inactivated FBS, 2 mM glutamine, and 1% antibiotics at 37 °C, in a humidified air incubator containing 5% CO<sub>2</sub>. It was plated at an appropriate density ( $1.0 \times 10^4$  cells/well) in 96-well plates and allowed to attach

for 24 h. Cells were then treated for 24 h with various concentrations of the compound  $\text{H}_2\text{TPPF}_{16}[\text{SC}_3\text{H}_7\text{O}_2]_4$  (0.06–10  $\mu\text{M}$ ).



**Figure 8.** Chemical structure of the synthesized porphyrin  $\text{H}_2\text{TPPF}_{16}[\text{SC}_3\text{H}_7\text{O}_2]_4$ .

A halogen/tungsten lamp (300–500 nm) (24 V, 250 W; Osram, Carnaxide, Portugal) was used as the light source. A 3% aqueous solution of  $\text{K}_2\text{Cr}_2\text{O}_7$  was placed between the lamp and the cells as a liquid cutoff filter to remove light below approximately 500 nm, thereby providing anity, at the cell level was 23–24  $\mu\text{W}/\text{cm}^2$ , as measured with an ILT 1400-A radiometer equipped with a SEL033 detector (ILT, Peabody, MA, USA), ensuring that all experiments were performed under the same irradiation conditions and exposure time. Before the experiments, a calibration was performed to ensure the uniformity of the light distribution and that the irradiation parameters (power, duration, distance from the source to the sample) were kept constant in all procedures. Additionally, experiments are performed with non-irradiated groups to validate the consistency of the method. The cells were irradiated continuously for 30 min. The total light dose can be estimated as fluence rate  $\times$  time: taking 23–24  $\mu\text{W}/\text{cm}^2$  for 30 min (1800 s) gives approximately 41–43  $\text{mJ}/\text{cm}^2$ . The use of the  $\text{K}_2\text{Cr}_2\text{O}_7$  cutoff filter to remove wavelengths  $<500$  nm indicates that irradiation was restricted to longer wavelengths, consistent with targeting the absorption region of many porphyrin-type photosensitizers and helping maximize selective Por activation while minimizing UV-induced cellular damage.

The cells were irradiated continuously for 30 min. The temperature to which the cells were exposed was carefully monitored to guarantee cell viability. The medium was changed and incubated again for 24 h. After this time, the adherent cells were fixed by adding cold 10% trichloroacetic acid (TCA; 100  $\mu\text{L}$ ) and incubated for 60 min at 4  $^\circ\text{C}$ . Plates were then washed with deionized water and subsequently dried; sulforhodamine B (SRB) solution (0.1% in 1% acetic acid, 100  $\mu\text{L}$ ) was then added to each plate well and incubated for 30 min at room temperature. Unbound SRB was removed by washing with 1% acetic acid. Plates were air-dried, the bound SRB was solubilized with 10 mM Tris (200  $\mu\text{L}$ ), and the absorbance was measured at 540 nm in an ELX800 Microplate Reader (Bio-Tek Instruments, Inc., Winooski, VT, USA). The results were expressed in compound concentration values that inhibited 50% of the net cell growth ( $\text{GI}_{50}$ ).

### 3.4. Development of PHA-Based Electrospun Membranes

#### 3.4.1. Preparation of Polymeric Formulations


- PHA/Por Electrospun Membranes

To produce electrospun membranes, polymeric formulations were prepared by dissolving 20% of PHA in chloroform and DMF (8:2,  $v/v$ ), which was constantly stirred at

50 °C for 3 h, and then overnight at room temperature. Afterward, the PS compound  $\text{H}_2\text{TPPF}_{16}[\text{SC}_3\text{H}_7\text{O}_2]_4$  was added at different concentrations ( $5.1 \times 10^{-7}$ ,  $1.02 \times 10^{-5}$ ,  $5.1 \times 10^{-5}$  and  $5.1 \times 10^{-4}$  M) to PHA solutions and left under stirring for 2 h in the dark.

- Multilayered PHA–Por/CS/PEO Electrospun Membranes

After the production of PHA and PHA/Por membranes, a multilayer membrane was developed following the scheme represented in Figure 9. The middle layer corresponds to the PHA electrospun membrane. The Por dissolved in DMF was incorporated into this layer at a concentration of  $5.1 \times 10^{-5}$  M, by immersing the PHA membrane in Por solution under constant stirring, followed by its drying at room temperature. Finally, the outer layers correspond to electrospun nanofiber membranes composed of CS/PEO. This solution was prepared with a total polymer concentration of 2% (*w/v*) (weight ratio 1:1) in 50% (*v/v*) acetic acid aqueous solution, as previously reported by some of us [29].



**Figure 9.** Schematic representation of the electrospun multilayered membrane. The middle layer is composed of a PHA electrospun membrane, followed by its post-electrospinning functionalization with Por solution, while the outer layers are composed of electrospun CS/PEO nanofibers.

### 3.4.2. Electrospinning Process

The previously prepared polymer solutions were electrospun in NF-103 electrospinning equipment from MECC (Fukuoka, Japan). Various parameters were tested to optimize the PHA electrospun membrane, including polymer concentration, solvents used, applied voltage, flow rate, distance between needle and collector, needle diameter, temperature, and humidity, and the optimized process parameters that allowed the formation of a stable jet and defect-free PHA fibers were 25 kV, 10 mL/h and 20 cm. CS/PEO nanofibers were produced according to the optimized values already described by Ribeiro et al. [29]. Table 1 describes in detail the optimized process conditions used to develop PHA and CS/PEO electrospun membranes.

**Table 1.** Optimized electrospinning conditions to produce PHA and CS/PEO membranes.

Parameters	Optimized Values	
	PHA and PHA/Por	CS/PEO
Voltage (kV)	25	29
Flow rate (mL/h)	10	4
Tip-to-collector distance (cm)	20	17
Needle diameter (mm)	0.61	0.41
Temperature (°C)	19–21	19–21
Humidity (%)	45–55	45–55

### 3.5. Characterization of the Developed Electrospun Membranes

#### 3.5.1. Field Emission Scanning Electron Microscopy (FESEM)

The morphology of the developed electrospun membranes was carried out using a high-resolution field emission scanning electron microscope, FEI Company NOVA 200 Nano SEM (Hillsboro, OR, USA), at an acceleration of 10 kV. The samples were previously removed from the aluminium foil and coated with a very thin film (20 nm) of Au-Pd (80–20% (*w/v*)) using a sputter coating apparatus, Cressington Company 208 HR (Watford, UK), coupled with a high-resolution film thickness controller, Cressington MTM-20. Images obtained by the FESEM technique were analyzed, and the fibers' diameters were determined using Image J 1.53a software (Wayne Rasband—National Institutes of Health, Bethesda, MD, USA), with measurements taken at 100 different locations for each sample.

#### 3.5.2. Water Contact Angle (WCA)

The hydrophilicity of the developed membranes was assessed using an OCA 15 contact angle system with an attached high-resolution chamber and a Drop Shape Analyzer DSA30E (Krüss Scientific, Hamburg, Germany). A volume of 5  $\mu\text{L}$  of distilled water was deposited on the surface of the samples, and the contact angle was measured by analyzing the shape of the droplet. Each sample was measured ten times at different locations to ensure uniformity.

#### 3.5.3. Attenuated Total Reflectance-Fourier Transform Infrared Spectroscopy (ATR-FTIR)

ATR-FTIR spectroscopy was used to study the chemical composition of electrospun membranes. This analysis was performed using an IRAffinity-1S instrument from SHIMADZU (Kyoto, Japan). Each spectrum was acquired in transmittance mode with a diamond ATR cell, accumulating data from 64 scans and with a resolution of  $2\text{ cm}^{-1}$  in the spectral range from  $400$  to  $4000\text{ cm}^{-1}$ . Samples were analyzed at three different locations to ensure uniformity.

#### 3.5.4. Thermogravimetric Analysis (TGA)

TGA was used to determine the thermal stability of the fibers obtained. This analysis was carried out using a STA 700 SCANSCI instrument (Vila Nova de Gaia, Portugal). The samples were subjected to a heating process from  $30$  to  $600\text{ }^\circ\text{C}$  under a nitrogen atmosphere at a constant heating rate of  $10\text{ }^\circ\text{C}/\text{min}$ . Three samples were analyzed to ensure uniformity.

#### 3.5.5. UV-Visible Absorption and Fluorescence Spectroscopy

The absorption spectrum of Por solution was obtained by UV-Vis spectroscopy using a SHIMADZU UV-1800 spectrophotometer (Nakagyo-ku, Japan). The fluorescence emission spectrum of Por solution and PHA/Por electrospun membranes was acquired in the wavelength range of  $300$  to  $800\text{ nm}$  using a FLEX spectrometer coupled to an LED light source with an excitation wavelength of  $365\text{ nm}$  (Sarspec, Lda, Vila Nova de Gaia, Porto, Portugal). Three measurements were performed for each sample to ensure homogeneity.

#### 3.5.6. Ground State Diffuse Reflectance (GSDR)

The PHA membranes with different Por concentrations were analyzed by GSDR. The reflectance spectra of the developed electrospun membranes were recorded in the wavelength range of  $300$  to  $800\text{ nm}$  using a SHIMADZU UV-2600 spectrophotometer with the ISR\_2600 Plus detector. The remission function ( $F(R)$ ) was calculated according to the Kubelka–Munk equation (Equation (1)).

$$F(R) = \frac{(1 - R)^2}{2R} = \frac{K}{S} \quad (1)$$

where  $R$  is the reflectance,  $K$  is the absorption coefficient and  $S$  is the scattering coefficient. To ensure uniformity and sample homogeneity, five independent measurements were performed at different locations across each sample.

### 3.5.7. Confocal Laser Scanning Microscopy (CLSM)

CLSM analysis was performed in an Olympus FLUOVIEW FV1000 confocal laser scanning microscope (Hachioji-shi, Japan). Electrospun membranes were collected for 3–5 min on a glass coverslip to enable a uniform distribution of fibers for image acquisition. The excitation and detection wavelengths were at 405 nm and 675–755 nm, respectively.

### 3.6. Drug Release Profile and Energy Dispersive Spectroscopy (EDS)

The release profile of Por was evaluated from different electrospun membranes architectures: PHA +  $5.1 \times 10^{-4}$  M and the multilayer PHA–Por ( $5.1 \times 10^{-5}$  M)/CS/PEO membranes. Each membrane ( $1 \times 1$  cm) was immersed in 4.5 mL of phosphate-buffered saline (PBS) solution with a pH of 7.4, and incubated at 37 °C, 30 rpm in an Ivymen orbital shaker (Barcelona, Spain). At predetermined time intervals, an aliquot was removed and analyzed by UV–Vis spectroscopy using a SHIMADZU UV-1800 spectrophotometer. Three replicates of each sample were evaluated.

EDS analysis of the multilayered membranes was conducted using a FlexSEM 1000 II SEM (Hitachi, Minato-ku, Japan) equipped with an XFlash 630Hc detector (Bruker, Billerica, MA, USA), after 24 h of immersion in PBS, at an accelerating voltage of 15 kV.

### 3.7. Evaluation of Cytotoxicity in the Dark and Irradiation of Electrospun Membranes in HeLa Cell Line

To evaluate the cytotoxicity in the dark and under light irradiation in HeLa cells of electrospun membranes, a section ( $1 \text{ cm} \times 1 \text{ cm}$ ) of each was used according to the procedure described in Section 3.3. However, in this case, the cells were placed in the well, and after 1 h, the membranes were added, followed by an incubation period of 24 h. Subsequently, the membranes were removed before cell irradiation (described in Section 3.3). The results were expressed as the percentage of inhibition of each membrane in the dark and under light irradiation.

## 4. Conclusions

In this study, two distinct approaches were followed to fabricate phototherapeutic platforms based on electrospun membranes for the treatment of cervical cancer using PDT. The first one consisted of producing single-layer PHA electrospun microfibers with Por as PS (PHA–Por membranes). Por was incorporated onto PHA microfibers at different concentrations ( $5.1 \times 10^{-7}$ ,  $1.02 \times 10^{-5}$ ,  $5.1 \times 10^{-5}$  and  $5.1 \times 10^{-4}$  M), selected based on the in vitro photodynamic effect observed against HeLa cells upon light irradiation. FESEM analysis revealed that overall PHA–Por membranes exhibited uniform, defect-free fibers with average diameters ranging from 0.9 to 1.9  $\mu\text{m}$ , compared to 1.3  $\mu\text{m}$  for PHA membranes, indicating that PS incorporation did not significantly affect fiber morphology or dimensions. The successful incorporation of Por into the membranes was further confirmed by GSDR spectroscopy, which revealed characteristic Por absorption bands consistent with those observed for Por in solution. These results were corroborated by fluorescence spectroscopy, which showed a fluorescence profile matching that of Por in solution. WCA measurements confirmed the hydrophobic nature of PHA membranes, and although Por incorporation resulted in a slight decrease in WCA, the membranes retained an overall surface hydrophobic character, promoting a negligible release of Por from the membranes. Considering the benefits of balanced hydrophilic surfaces over hydrophobic ones to foster cell–material interactions, a second approach was pursued.

A multilayer structure was produced by sequential electrospinning, consisting of a PHA-based membrane, post-functionalized with Por, as the middle layer, and CS/PEO as the outer layers (PHA–Por/CS/PEO). These multilayer membranes exhibited a substantial decrease in WCA, confirming a hydrophilic surface, while ATR-FTIR spectra confirmed the successful coating with CS/PEO nanofibers. GSDR and fluorescence spectroscopy further confirmed the presence and retention of porphyrin's photophysical properties. Moreover, PHA–Por/CS/PEO membranes displayed significantly higher cytotoxicity on HeLa cells' proliferation under light irradiation compared to dark conditions, achieving maximum inhibition of approximately 30% when exposed to radiation. These results were corroborated by the continuous and sustained Por release over a 24 h period. However, it should be noted that these observations are based on a single cancer cell line, and further studies using additional cell lines are needed to fully validate the therapeutic potential of this system.

Collectively, the control over the composition and architectures of the fibrous electrospun structures, together with the strategic incorporation of PSs, enables full exploitation of their physicochemical and photodynamic properties, thereby enhancing therapeutic efficiency while allowing personalized adaptations to meet patients' specific characteristics. From a translational perspective, several considerations must be addressed to support the potential clinical application of the developed multilayer structure. The membrane demonstrated adequate mechanical flexibility and structural integrity, which may facilitate handling and surgical placement at the treatment site. Light activation of the photosensitizer could be performed using available LED systems, with irradiation parameters adjusted according to tissue depth and anatomical location. Additionally, sterilization procedures require further validation to guarantee the preservation of membrane integrity and photodynamic performance following processing. The electrospinning technique itself offers significant advantages in terms of scalability, as optimization of production parameters enables large-scale manufacturing. Nevertheless, *in vivo* studies, along with evaluation of regulatory requirements, remain essential to fully establish the safety, therapeutic efficacy and manufacturability of the system prior to clinical translation. In addition, because the photosensitizer is released locally over time from the multilayer membrane, future *in vivo* implementation should follow a release-informed drug–light interval strategy, with irradiation timing and light dose adjusted to the *in situ* release kinetics and anatomical accessibility of the target tissue. While the present results provide initial evidence on the system's performance, future studies, including replicate-based biological experiments and further statistical analysis, should be performed to enhance the robustness and reproducibility of the results.

Overall, this work underscores the innovative potential of localized drug delivery platforms based on multilayer electrospun membranes combined with targeted PDT for cancer treatment. This strategy represents a significant advancement toward minimally invasive and localized treatments, opening new opportunities for personalized and highly effective therapeutic interventions in oncology.

**Author Contributions:** Conceptualization, C.V.G., S.M.C. and D.P.F.; methodology, C.V.G. and S.M.C.; validation, S.M.C., R.C.C., L.M.O.L., R.C.C. and D.P.F.; investigation, C.V.G., S.M.C., J.S.O., R.C.C. and L.M.O.L.; resources, L.M.O.L. and D.P.F.; writing—original draft C.V.G., S.M.C., J.S.O., L.M.O.L. and R.C.C.; writing—review and editing, R.C.C., L.M.O.L., R.F. and D.P.F.; supervision: R.F. and D.P.F.; funding acquisition, D.P.F. and R.F. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by national funds through FCT—Fundação para a Ciência e a Tecnologia, I.P. and Programa de Recuperação e Resiliência (PRR) through NextGenerationEU from the European Union, under the Strategic Projects UID/00264/2025 and UID/PRR/00264/2025 of

the 2C2T—Centro de Ciência e Tecnologia Têxtil (<https://doi.org/10.54499/UID/00264/2025> and <https://doi.org/10.54499/UID/PRR/00264/2025>), and under the project DRI/India/0447/2020 (<https://doi.org/10.54499/DRI/India/0447/2020>); National funding by FCT. P.I. through the scientific employment program contract for the contract of R. Calhella (CEEC Institutional DOI:10.54499/CEECINST/00016/2018/CP1505/CT0009) and for the financial support through national funds FCT/MCTES (PIDDAC) to CIMO (UIDB/00690/2020 and UIDP/00690/2020) and SusTEC (LA/P/0007/2020). LAQV-REQUIMTE (LA/P/0008/2020, DOI: 10.54499/LA/P/0008/2020; UIDP/50006/2020, DOI: 10.54499/UIDP/50006/2020; and UIDB/50006/2020, DOI: 10.54499/UIDB/50006/2020), and COMPETE2030-FEDER-00799000.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** The original contributions presented in this study are included in the article. Further inquiries can be directed to the corresponding authors.

**Conflicts of Interest:** The authors declare no conflicts of interest.

## Abbreviations

The following abbreviations are used in this manuscript:

ATR-FTIR	Attenuated Total Reflectance-Fourier Transform Infrared Spectroscopy
CLSM	Confocal Laser Scanning Microscopy
CS	Chitosan
DDS	Drug Delivery Systems
DMF	Dimethylformamide
ECM	Extracellular Matrix
EDS	Energy Dispersive Spectroscopy
EMA	European Medicines Agency
FDA	Food and Drug Administration
FESEM	Field Emission Scanning Electron Microscopy
GSDR	Ground State Diffuse Reflectance
HPV	Human Papillomavirus
PBS	Phosphate-Buffered Saline
PDT	Photodynamic Therapy
PEO	Polyethylene Oxide
PHA	Polyhydroxyalkanoate
PLA	Polylactic acid
PS	Photosensitizer
ROS	Reactive Oxygen Species
TGA	Thermogravimetric Analysis
WCA	Water Contact Angle

## References

1. Cancer. Available online: <https://www.who.int/news-room/fact-sheets/detail/cancer> (accessed on 15 January 2026).
2. Cervical Cancer. Available online: <https://www.who.int/news-room/fact-sheets/detail/cervical-cancer> (accessed on 14 January 2026).
3. Habib, N.; Idoubba, S.; Fitcher, F.; Pieri, E.; Schettini, G.; Giorgi, M.; Negre, R.R.; Gabriele, C. Cervical Cancer Treatment and Fertility: What We Know and What We Do. *Cancers* **2025**, *17*, 3057. [[CrossRef](#)]
4. Burmeister, C.A.; Khan, S.F.; Schäfer, G.; Mbatani, N.; Adams, T.; Moodley, J.; Prince, S. Cervical Cancer Therapies: Current Challenges and Future Perspectives. *Tumour Virus Res.* **2022**, *13*, 200238. [[CrossRef](#)]
5. Le Guévelou, J.; Selleret, L.; Laas, E.; Lecuru, F.; Kissel, M. Cervical Cancer Associated with Pregnancy: Current Challenges and Future Strategies. *Cancers* **2024**, *16*, 1341. [[CrossRef](#)] [[PubMed](#)]
6. Liu, Y.; Li, R.; Li, C.; Liu, Z.; Duan, L.; Huang, Q.; Geng, L.; Hou, J.; Wei, L.; Wu, R. Photodynamic Therapy Compared with Loop Electrosurgical Excision Procedure in Patients with Cervical High-Grade Squamous Intraepithelial Lesion. *Sci. Rep.* **2024**, *14*, 27090. [[CrossRef](#)]

7. Costa, S.M.; Figueiro, R.; Ferreira, D.P. Drug Delivery Systems for Photodynamic Therapy: The Potentiality and Versatility of Electrospun Nanofibers. *Macromol. Biosci.* **2022**, *22*, 2100512. [[CrossRef](#)] [[PubMed](#)]
8. Friães, S.; Lima, E.; Boto, R.E.; Ferreira, D.; Fernandes, J.R.; Ferreira, L.F.V.; Silva, A.M.; Reis, L.V. Photophysicochemical Properties and In Vitro Phototherapeutic Effects of Iodoquinoline- and Benzothiazole-Derived Unsymmetrical Squaraine Cyanine Dyes. *Appl. Sci.* **2019**, *9*, 5414. [[CrossRef](#)]
9. Plaetzer, K.; Krammer, B.; Berlanda, J.; Berr, F.; Kiesslich, T. Photophysics and Photochemistry of Photodynamic Therapy: Fundamental Aspects. *Lasers Med. Sci.* **2009**, *24*, 259–268. [[CrossRef](#)]
10. Al-Jamal, A.N.; Al-Hussainy, A.F.; Mohammed, B.A.; Abbas, H.H.; Kadhim, I.M.; Ward, Z.H.; Mahapatra, D.K.; Joseph, T.M.; Kianfar, E.; Thomas, S. Photodynamic Therapy (PDT) in Drug Delivery: Nano-Innovations Enhancing Treatment Outcomes. *Health Sci. Rev.* **2025**, *14*, 100218. [[CrossRef](#)]
11. Ferreira, D.P.; Conceição, D.S.; Calhelha, R.C.; Sousa, T.; Socoteanu, R.; Ferreira, I.C.F.R.; Vieira Ferreira, L.F. Porphyrin Dye into Biopolymeric Chitosan Films for Localized Photodynamic Therapy of Cancer. *Carbohydr. Polym.* **2016**, *151*, 160–171. [[CrossRef](#)]
12. Costa, S.M.; Lourenço, L.M.O.; Calhelha, R.C.; Calejo, I.; Barrias, C.C.; Figueiro, R.; Ferreira, D.P. Localized Cancer Photodynamic Therapy Approach Based on Core–Shell Electrospun Nanofibers. *Mater. Adv.* **2024**, *5*, 6489–6500. [[CrossRef](#)]
13. Cai, Y.; Chai, T.; Nguyen, W.; Liu, J.; Xiao, E.; Ran, X.; Ran, Y.; Du, D.; Chen, W.; Chen, X. Phototherapy in Cancer Treatment: Strategies and Challenges. *Signal Transduct. Target. Ther.* **2025**, *10*, 115. [[CrossRef](#)]
14. Pacheco, C.; Baião, A.; Ding, T.; Cui, W.; Sarmiento, B. Recent Advances in Long-Acting Drug Delivery Systems for Anticancer Drug. *Adv. Drug Deliv. Rev.* **2023**, *194*, 114724. [[CrossRef](#)] [[PubMed](#)]
15. Elfawal, G.F.; Šišková, A.O.; Andicsová, A.E. Electrospinning: A Game-Changer in Fiber Production and Practical Applications. *Fibers Polym.* **2025**, *26*, 4133–4160. [[CrossRef](#)]
16. Cho, Y.; Beak, J.W.; Sagong, M.; Ahn, S.; Nam, J.S.; Kim, I.D. Electrospinning and Nanofiber Technology: Fundamentals, Innovations, and Applications. *Adv. Mater.* **2025**, *37*, 2500162. [[CrossRef](#)] [[PubMed](#)]
17. Rocha, J.M.; Sousa, R.P.C.L.; Araújo, J.C.; Costa, S.M.; Antunes, W.; Rocha, V.; Figueiro, R.; Ferreira, D.P. PAN/CA-Based Electrospun Membranes for Air Filtration and Active Microorganism Degradation. *Mater. Chem. Phys.* **2026**, *349*, 131861. [[CrossRef](#)]
18. Xing, J.; Zhang, M.; Liu, X.; Wang, C.; Xu, N.; Xing, D. Multi-Material Electrospinning: From Methods to Biomedical Applications. *Mater. Today Bio* **2023**, *21*, 100710. [[CrossRef](#)]
19. Jin, T.; Li, Y.; Li, Q.; Hu, X.; Zhang, J.; Luo, L. Flexible Cervical Photodynamic Therapy Device. *Transl. Biophotonics* **2024**, *6*, e70001. [[CrossRef](#)]
20. Wang, X.; Liu, S.; Guan, Y.; Ding, J.; Ma, C.; Xie, Z. Vaginal Drug Delivery Approaches for Localized Management of Cervical Cancer. *Adv. Drug Deliv. Rev.* **2021**, *174*, 114–126. [[CrossRef](#)]
21. Ribeiro, A.S.; Costa, S.M.; Ferreira, D.P.; Abidi, H.; Figueiro, R. Development of Chitosan-Gelatin Nanofibers with Cellulose Nanocrystals for Skin Protection Applications. *Key Eng. Mater.* **2021**, *893*, 45–55. [[CrossRef](#)]
22. Menagadevi, M.; Nirmala, M.; Thiyagarajan, D. Biomedical Applications of Natural and Synthetic Polymers: A Mechanical Perspective. *Biomed. Mater. Devices* **2025**, *2025*, 1–25. [[CrossRef](#)]
23. Rebelo, R.; Fernandes, M.; Figueiro, R. Biopolymers in Medical Implants: A Brief Review. *Procedia Eng.* **2017**, *200*, 236–243. [[CrossRef](#)]
24. Prakash, P.; Lee, W.H.; Loo, C.-Y.; Wong, H.S.J.; Parumasivam, T. Advances in Polyhydroxyalkanoate Nanocarriers for Effective Drug Delivery: An Overview and Challenges. *Nanomaterials* **2022**, *12*, 175. [[CrossRef](#)]
25. Paul, V.; Pandhi, S.; Mahato, D.K.; Agarwal, A.; Tripathi, A.D. Polyhydroxyalkanoates (PHAs) and Its Copolymer Nanocarrier Application in Cancer Treatment: An Overview and Challenges. *Int. J. Biol. Macromol.* **2024**, *277*, 134201. [[CrossRef](#)]
26. Paterlini, T.T.; Nogueira, L.F.B.; Tovani, C.B.; Cruz, M.A.E.; Derradi, R.; Ramos, A.P. The Role Played by Modified Bioinspired Surfaces in Interfacial Properties of Biomaterials. *Biophys. Rev.* **2017**, *9*, 683–698. [[CrossRef](#)] [[PubMed](#)]
27. Ribeiro, A.S.; Costa, S.M.; Ferreira, D.P.; Calhelha, R.C.; Barros, L.; Stojković, D.; Soković, M.; Ferreira, I.C.F.R.; Figueiro, R. Chitosan/Nanocellulose Electrospun Fibers with Enhanced Antibacterial and Antifungal Activity for Wound Dressing Applications. *React. Funct. Polym.* **2021**, *159*, 104808. [[CrossRef](#)]
28. Injorhor, P.; Trongsatitkul, T.; Wittayakun, J.; Ruksakulpiwat, C.; Ruksakulpiwat, Y. Biodegradable Polylactic Acid-Polyhydroxyalkanoate-Based Nanocomposites with Bio-Hydroxyapatite: Preparation and Characterization. *Polymers* **2023**, *15*, 1261. [[CrossRef](#)]
29. Kervran, M.; Vagner, C.; Cochez, M.; Ponçot, M.; Saeb, M.R.; Vahabi, H. Thermal Degradation of Polylactic Acid (PLA)/Polyhydroxybutyrate (PHB) Blends: A Systematic Review. *Polym. Degrad. Stab.* **2022**, *201*, 109995. [[CrossRef](#)]
30. He, Z.Y.; Pan, Z.J. Biobased Polymer SF/PHBV Composite Nanofiber Membranes as Filtration and Protection Materials. *J. Text. Inst.* **2023**, *114*, 55–65. [[CrossRef](#)]
31. Thanh, N.H.; Olekhovich, R.; Sitnikova, V.; Kremleva, A.; Snetkov, P.; Uspenskaya, M. PHB/PEG Nanofiber Mat Obtained by Electrospinning and Their Performances. *Technologies* **2023**, *11*, 48. [[CrossRef](#)]

32. Rehakova, V.; Pernicova, I.; Kourilova, X.; Sedlacek, P.; Musilova, J.; Sedlar, K.; Koller, M.; Kalina, M.; Obruca, S. Biosynthesis of Versatile PHA Copolymers by Thermophilic Members of the Genus *Aneurinibacillus*. *Int. J. Biol. Macromol.* **2023**, *225*, 1588–1598. [[CrossRef](#)]
33. Rebocho, A.T.; Pereira, J.R.; Neves, L.A.; Alves, V.D.; Sevrin, C.; Grandfils, C.; Freitas, F.; Reis, M.A.M. Preparation and Characterization of Films Based on a Natural P(3HB)/Mcl-PHA Blend Obtained through the Co-Culture of *Cupriavidus Necator* and *Pseudomonas Citronellolis* in Apple Pulp Waste. *Bioengineering* **2020**, *7*, 34. [[CrossRef](#)]
34. Yao, H.; Wu, L.P.; Chen, G.Q. Synthesis and Characterization of Electroconductive PHA-Graft-Graphene Nanocomposites. *Biomacromolecules* **2018**, *20*, 645–652. [[CrossRef](#)]
35. Mai, J.; Chan, C.M.; Colwell, J.; Pratt, S.; Laycock, B. Characterisation of End Groups of Hydroxy-Functionalised Scl-PHAs Prepared by Transesterification Using Ethylene Glycol. *Polym. Degrad. Stab.* **2022**, *205*, 110123. [[CrossRef](#)]
36. Alfano, S.; Pagnanelli, F.; Martinelli, A. Rapid Estimation of Poly(3-Hydroxybutyrate-Co-3-Hydroxyvalerate) Composition Using ATR-FTIR. *Polymers* **2023**, *15*, 4127. [[CrossRef](#)]
37. Aman Mohammadi, M.; Ramezani, S.; Hosseini, H.; Mortazavian, A.M.; Hosseini, S.M.; Ghorbani, M. Electrospun Antibacterial and Antioxidant Zein/Polylactic Acid/Hydroxypropyl Methylcellulose Nanofibers as an Active Food Packaging System. *Food Bioprocess Technol.* **2021**, *14*, 1529–1541. [[CrossRef](#)]
38. Wu, Z.; Zhang, Z.; Wei, W.; Yin, Y.; Huang, C.; Ding, J.; Duan, Q. Investigation of a Novel Poly (Lactic Acid) Porous Material Toughened by Thermoplastic Polyurethane. *J. Mater. Sci.* **2022**, *57*, 5456–5466. [[CrossRef](#)]
39. Lourenço, L.M.O.; Beirão, S.; Melo, A.; Fernandes, R.; Tomé, J.P.C. Thioglycerol-Porphyrin, -Chlorin, and -Phthalocyanine Derivatives for Photodynamic Therapy of UM-UC-3 Bladder Cancer Cells. *J. Photochem. Photobiol. A Chem.* **2023**, *442*, 114768. [[CrossRef](#)]
40. Lourenço, L.M.O.; Resende, J.; Iglesias, B.A.; Castro, K.; Nakagaki, S.; Lima, M.J.; Da Cunha, A.F.; Neves, M.G.P.M.S.; Cavaleiro, J.A.S.; Tomé, J.P.C. Synthesis, Characterization and Electrochemical Properties of Meso-Thiocarboxylate-Substituted Porphyrin Derivatives. *J. Porphyr. Phthalocyanines* **2014**, *18*, 967–974. [[CrossRef](#)]
41. Gupta, D.; Roy, P.; Sharma, R.; Kasana, R.; Rathore, P.; Gupta, T.K. Recent Nanotheranostic Approaches in Cancer Research. *Clin. Exp. Med.* **2024**, *24*, 8. [[CrossRef](#)]
42. Zannotti, M.; Giovannetti, R.; Minofar, B.; Řeha, D.; Plačková, L.; D’Amato, C.A.; Rommozzi, E.; Dudko, H.V.; Kari, N.; Minicucci, M. Aggregation and Metal-Complexation Behaviour of THPP Porphyrin in Ethanol/Water Solutions as Function of PH. *Spectrochim. Acta A Mol. Biomol. Spectrosc.* **2018**, *193*, 235–248. [[CrossRef](#)] [[PubMed](#)]
43. Butkute, A.; Kazlauskė, E.; Mlynska, A.; Peciukaiyte, E.; Karabanovas, V.; Rotomskis, R.; Steponkiene, S. Unveiling Theranostics: Nanocomplex-Assisted Photodynamic Eradication of Aggressive Cancer Cells and Modulation of Tumor-Associated Macrophages. *Int. J. Nanomed.* **2025**, *20*, 9787. [[CrossRef](#)] [[PubMed](#)]
44. Li, Z.; Yang, J.; Loh, X.J. Polyhydroxyalkanoates: Opening Doors for a Sustainable Future. *NPG Asia Mater.* **2016**, *8*, e265. [[CrossRef](#)]
45. Sutthiwanjampa, C.; Hong, S.; Kim, W.J.; Kang, S.H.; Park, H. Hydrophilic Modification Strategies to Enhance the Surface Biocompatibility of Poly(Dimethylsiloxane)-Based Biomaterials for Medical Applications. *Adv. Mater. Interfaces* **2023**, *10*, 2202333. [[CrossRef](#)]
46. Liu, T.; Zhang, Z.; Liu, J.; Dong, P.; Tian, F.; Li, F.; Meng, X. Electrospun Kaolin-Loaded Chitosan/PEO Nanofibers for Rapid Hemostasis and Accelerated Wound Healing. *Int. J. Biol. Macromol.* **2022**, *217*, 998–1011. [[CrossRef](#)]
47. Ebrahimi, S.R.; Nikbakht, M.; Shams Abadi, M.S.; Gholipour, A.; Bagheri, M.; Validi, M. Investigation of Biocompatibility and Antibacterial Properties of Electrospun Chitosan/Polyethylene Oxide-Based Scaffolds Containing Propolis Extract against *Enterococcus faecalis*, *Pseudomonas aeruginosa*, *Staphylococcus aureus* and *Staphylococcus epidermidis*. *Heliyon* **2025**, *11*, e42228. [[CrossRef](#)] [[PubMed](#)]
48. Shah, J.; Patel, D.; Ranavavare, D.; Hudson, D.; Tran, M.; Schloss, R.; Langrana, N.; Berthiaume, F.; Kumar, S. Recent Advancements in Chitosan-Based Biomaterials for Wound Healing. *J. Funct. Biomater.* **2025**, *16*, 45. [[CrossRef](#)]
49. Zhao, J.; Chen, L.; Ma, A.; Bai, X.; Zeng, Y.; Liu, D.; Liu, B.; Zhang, W.; Tang, S. Recent Advances in Coaxial Electrospun Nanofibers for Wound Healing. *Mater. Today Bio* **2024**, *29*, 101309. [[CrossRef](#)]
50. Vojoudi, E.; Babaloo, H. Application of Electrospun Nanofiber as Drug Delivery Systems: A Review. *Pharm. Nanotechnol.* **2023**, *11*, 10–24. [[CrossRef](#)]
51. Wildy, M.; Lu, P. Electrospun Nanofibers: Shaping the Future of Controlled and Responsive Drug Delivery. *Materials* **2023**, *16*, 7062. [[CrossRef](#)]
52. Costa, S.M.; Mattos, B.D.; Calhelha, R.C.; Zhu, Y.; Lima, E.; Reis, L.V.; Rojas, O.J.; Fangueiro, R.; Ferreira, D.P. Electrospun Polycaprolactone Membranes Functionalized with Nanochitin for Enhanced Bioactivity in Localized Cancer Photodynamic Therapy. *Carbohydr. Polym. Technol. Appl.* **2025**, *11*, 100895. [[CrossRef](#)]

**Disclaimer/Publisher’s Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.